SCHEMBL24313810

SCHEMBL24313810

COc1ccc(CC(C)=O)cc1S(=O)(=O)NC(=O)c1cc2c(F)cc(C3CC3)cc2o1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.37
KCNH2 Q12809 2/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
THRB P10828 1/20 0.36
TSHR P16473 1/20 0.36
POLB P06746 1/20 0.35
TRIM24 O15164 2/20 0.35
BRPF1 P55201 1/20 0.35
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HTT P42858 2/20 0.34
UBE2N P61088 1/20 0.34
CLK1 P49759 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24313774 0.89 TRIM24 (0.41) MCHR1KCNH2L3MBTL1TRIM24BRPF1
SCHEMBL24314184 0.86 ALDH1A1 (0.43) MCHR1KCNH2L3MBTL1TRIM24BRPF1
SCHEMBL29587808 0.86 ALDH1A1 (0.43) MCHR1KCNH2L3MBTL1TRIM24BRPF1
SCHEMBL24333754 0.83 L3MBTL1 (0.38) MCHR1KCNH2L3MBTL1THRBTSHR
SCHEMBL24314247 0.82 MEN1 (0.36) L3MBTL1TSHRTRIM24MEN1ALDH1A1
SCHEMBL24314237 0.81 MRGPRX1 (0.38) MCHR1KCNH2L3MBTL1TSHRMEN1
SCHEMBL24313811 0.81 MCHR1 (0.38) MCHR1KCNH2L3MBTL1POLBALDH1A1
SCHEMBL24313760 0.80 SCN9A (0.35) L3MBTL1TSHRMEN1ALDH1A1KMT2A
SCHEMBL24333741 0.78 TRIM24 (0.41) MCHR1KCNH2L3MBTL1TRIM24BRPF1
SCHEMBL24313979 0.78 CYP1A2 (0.37) MCHR1KCNH2L3MBTL1THRBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4229045-B1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BROAD INST INC (US) 2025-11-12 EP claimed
EP-4229045-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute Inc. (US) 2023-08-23 EP claimed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO claimed
US-20240287048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-29 US disclosed
EP-4229045-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute Inc. (US) 2023-08-23 EP disclosed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A MCHR1 4391/4885KCNH2 1005/4885L3MBTL1 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.